Home » FDA APPROVES ENDOLOGIX'S POWERLINK-120 ELG
FDA APPROVES ENDOLOGIX'S POWERLINK-120 ELG
Endologix has received FDA approval to market new short body-short limb variants of the PowerlinkSystem endoluminal stent graft (ELG) for the minimally invasive treatment of abdominal aortic aneurysms (AAA).
The two Powerlink-120 models should address the 5 to 10 percent of AAA patients currently excluded from treatment because of "anatomical considerations," the company said. Endologix plans to market the new devices beginning in May.
KEYWORDS FDAnews Device Daily Bulletin
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May